Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs) remain a major obstacle for the optimal application of CCB in cancer. Here, we analyzed B cell changes in patients with melanoma following treatm...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Invest
Asıl Yazarlar: Das, Rituparna, Bar, Noffar, Ferreira, Michelle, Newman, Aaron M., Zhang, Lin, Bailur, Jithendra Kini, Bacchiocchi, Antonella, Kluger, Harriet, Wei, Wei, Halaban, Ruth, Sznol, Mario, Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2018
Konular:
Concise Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5785243/
https://ncbi.nlm.nih.gov/pubmed/29309048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96798
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller